An FDA advisory committee voted by a majority to recommend broader access to six peptides, including BPC-157 and TB-500, for compounding pharmacies. The panel held a two-day hearing in Maryland to review seven peptides, and if the FDA approves, licensed pharmacies could prepare them for valid…
An advisory committee to the U.S. Food and Drug Administration has voted by a majority to recommend that six specific peptides be made more accessible to patients through licensed compounding pharmacies. The decision came after a two-day hearing held by the FDA's Pharmacy Compounding Advisory Committee in Maryland during the week of July 21, 2026. The panel reviewed seven popular peptides that have gained widespread attention for potential uses ranging from weight loss to wound healing.
Peptides are short chains of amino acids that help regulate functions such as metabolism, growth and tissue repair, according to Cleveland Clinic. Some peptides are already used in FDA-approved medications, including insulin and GLP-1 weight-loss drugs. Others, however, are experimental compounds that are marketed for wellness or performance and remain under federal review.
The committee considered whether each of the seven peptides should be added to the Section 503A Bulks List. If ultimately approved by the FDA, licensed compounding pharmacies could prepare these peptides for valid prescriptions. This would allow patients to obtain them through regulated channels instead of relying on unregulated online vendors, which have been a growing source of concern.
Dr. Alex Tatem, a board-certified urologist in Indiana, urged the panel to weigh real-world safety data on peptides during the hearings. He argued that years of patient use have shown a promising safety profile for many of these compounds. His comments highlighted the tension between the desire for broader access and the need for rigorous safety oversight.
The committee voted in favor of loosening restrictions on six of the seven peptides under review, according to Reuters. The list includes BPC-157, proposed to treat ulcerative colitis; TB-500, proposed for wound healing; KPV, proposed for wound healing and inflammatory conditions; MOTS-c, proposed to treat obesity and osteoporosis; Semax, proposed to treat cerebral ischemia, migraine and trigeminal neuralgia; and Epitalon, proposed to treat insomnia. The seventh peptide was not recommended by the panel.
While some peptide experts celebrated the vote as a step toward broader access to potential life-improving drugs, others expressed concern that there is not enough data on safety and efficacy. The FDA will now consider the committee's recommendation before making a final decision. Jim LaValle, a Texas-based clinical pharmacist and chair of the International Peptide Society, testified at the hearings and emphasized that restrictions still exist.
“This was not FDA approval, nor was it a blanket endorsement of every peptide, every use or unrestricted access,” LaValle said. He is also a board-certified nutritionist. “I have said throughout this process that you do not solve a quality problem by forcing the market underground.”
LaValle expressed encouragement about the committee’s recommendation because it creates an opportunity to move patients away from unverified research use only RUO products, otherwise known as grey market products, and toward a more accountable medical pathway. He noted that his work with the International Peptide Society focuses on training clinicians about the potential benefits and risks of peptide therapies as interest in the compounds grows.
LaValle described the “right model” as access with guardrails, qualified clinicians, licensed pharmacies, validated quality testing and “meaningful” patient follow-up. “My hope is that the FDA follows the recommendation with a transparent, science-driven process; establishes clear, peptide-specific standards; and follows the guidance for approving a substance that meets the FDA’s current regulations,” he said.
This process includes checking that both the active ingredient and the final product meet quality standards, and setting up a system for tracking and reporting any side effects. He also noted that the evidence is not equally mature across all peptides that are approved by the FDA.
“The peptide revolution is here,” LaValle said. “However, don’t expect miracles. Better choices related to diet, exercise, gut health, sleep, stress and managing metabolic health, guided by regular lab assessments, should be the goal.” He added that in some cases, peptides can play an important part on the journey of performance aging and repair. “The American public should understand that nothing changed overnight.”
LaValle emphasized that the advisory committee's vote was only a recommendation, not a final FDA decision, and noted that compounded medications are regulated differently than FDA-approved drugs. He warned that people should avoid products sold online as “research use only” and should not self-experiment. “Any consideration of peptide therapy should involve a qualified licensed clinician and a legitimate licensed pharmacy,” he concluded.
Peptides referenced: BPC-157, TB-500, MOTS-c, Epithalon, Semax, GLP-1.
Related reading: Thyroid Meds Recalled Nationwide; GLP-1 Hair Loss Question; PMOS Prevalence Reported, FDA Updates Draft Guidance for Generics of Top Weight Loss Drugs, FDA Drafts Product-Specific Guidances for Generic Peptide Drugs, Semaglutide Maintains Reduced Calorie Consumption Beyond One Year.